SPLUNC1: a novel marker of cystic fibrosis exacerbations.
Sara KhanalMegan WebsterNaiqian NiuJana ZielonkaMyra NunezGeoffrey ChuppMartin D SladeLauren CohnMaor SaulerJose L GomezRobert TarranLokesh SharmaCharles S Dela CruzMarie EganTheresa LagunaClemente J BrittoPublished in: The European respiratory journal (2021)
In acute CF care, low SPLUNC1 levels could support a decision to increase airway clearance or to initiate pharmacological interventions. In asymptomatic, stable patients, low SPLUNC1 levels could inform changes in clinical management to improve long-term disease control and clinical outcomes in CF.
Keyphrases
- cystic fibrosis
- pseudomonas aeruginosa
- end stage renal disease
- lung function
- ejection fraction
- newly diagnosed
- healthcare
- chronic kidney disease
- liver failure
- chronic obstructive pulmonary disease
- palliative care
- prognostic factors
- physical activity
- chronic pain
- respiratory failure
- pain management
- patient reported outcomes
- aortic dissection
- mechanical ventilation
- extracorporeal membrane oxygenation